Masanori Sakurai

In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.

M Iigo, Masanori Sakurai, Tomohide Tamura et al. · PubMed · 1988 · 132 citations

Multiple Injections, Immunology, Pathology +16

Phase II Study of UFT in Patients With Advanced Non-Small Cell Lung Cancer

Naoto Keicho, Nagahiro Saijo, Tetsu Shinkai et al. · Japanese Journal of Clinical Oncology · 1986 · 42 citations

Advanced Lung Disease, Medicine, Cancer Management +15

Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan)

Masanori Sakurai, Tetsu Shinkai, Kenji Eguchi et al. · Journal of Cancer Research and Clinical Oncology · 1987 · 33 citations · Full text

Prognostic Factors, Medicine, Prognosis +9

Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.

Tomohide Tamura, Y Sasaki, T Shinkai et al. · PubMed · 1989 · 30 citations

Immunology, Synergistic Antitumor Effect, Pharmacotherapy +19

Microbiological and clinical study of methicillin-resistant Staphylococcus aureus (MRSA) carrying VraS mutation: changes in susceptibility to glycopeptides and clinical significance

Yoshihisa Kato, Takahisa Suzuki, Takashi Ida et al. · International Journal of Antimicrobial Agents · 2007 · 28 citations

Vras Mutation, Methicillin-resistant Staphylococcus Aureus, Health Sciences +7